The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Emerging Therapies for Hepatocellular Carcinoma (HCC)
Open accessAbstract
Hepatocellular carcinoma (HCC) arises from hepatocytes and accounts for 90% of primary liver cancer. According to Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 2020, globally HCC is the sixth most common cancer and the third most common cause of cancer-related deaths. Reasons for HCC prognosis remaining dismal are that HCC is asymptomatic in its early stages, leading to late diagnosis, and it is markedly resistant to conventional chemo- and radiotherapy. Liver transplantation is the treatment of choice in early stages, while surgical resection, radiofrequency ablation (RFA) and trans arterial chemoembolization (TACE) are Food and Drug Administration (FDA)-approved treatments for advanced HCC. Additional first line therapy for advanced HCC includes broad-spectrum tyrosine kinase inhibitors (TKIs), such as sorafenib and lenvatinib, as well as a combination of immunotherapy and anti-angiogenesis therapy, namely atezolizumab and bevacizumab. However, these strategies provide nominal extension in the survival curve, cause broad spectrum toxic side effects, and patients eventually develop therapy resistance. Some common mutations in HCC, such as in telomerase reverse transcriptase (TERT), catenin beta 1 (CTNNB1) and tumor protein p53 (TP53) genes, are still considered to be undruggable. In this context, identification of appropriate gene targets and specific gene delivery approaches create the potential of gene- and immune-based therapies for the safe and effective treatment of HCC. This review elaborates on the current status of HCC treatment by focusing on potential gene targets and advanced techniques, such as oncolytic viral vectors, nanoparticles, chimeric antigen receptor (CAR)-T cells, immunotherapy, and clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9), and describes future prospects in HCC treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
A simplified system for generating recombinant adenoviruses
He, T.-C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., & Vogelstein, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2509 · Cited by 3,206
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
Lipid Nanoparticle Systems for Enabling Gene Therapies
Cullis, P. R., & Hope, M. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.013 · Cited by 1,208
Finn, R. S., Ikeda, M., Zhu, A. X., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00808 · Cited by 1,167
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · cited 1×
“Interaction between PD-1 with PD-1 ligand 1 (PDL1/B7H1/PDCDL1/CD274), expressed by tumor cells, results in dephosphorylation of T cell activating kinases, causing T cell activation, and as such the inhibition of PD-1/PD-L1 restores function of effector CD8+ T cells [94].”
BackgroundRen, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00252-7 · Cited by 1,124 · cited 1×
“ORIENT-32 is a randomized, open-label phase 2/3 study done in China comparing the efficacy of sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab mimic, versus sorafenib as a first-line treatment for unresectable HBV-HCC [104].”
BackgroundImmune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976
CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea
Marraffini, L. A., & Sontheimer, E. J. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2749 · Cited by 919
Fu, J., Xu, D., Liu, Z., Shi, M., Zhao, P., Fu, B., Zhang, Z., Yang, H., Zhang, H., Zhou, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.102 · Cited by 897 · cited 1×
“It has been shown that increased expression of CD4+/CD25+/forkhead/winged helix transcription factor (FoxP3)+ Tregs correlate with reduced effector CD8+ T cell infiltration in the tumors and poor survival in HCC patients [91].”
BackgroundGao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
Non Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 761
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Lee, M. S., Ryoo, B.-Y., Hsu, C.-H., Numata, K., Stein, S., Verret, W., Hack, S. P., Spahn, J., Liu, B., Abdullah, H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30156-x · Cited by 562
High, K. A., & Roncarolo, M. G. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1706910 · Cited by 555
Park, B.-H., Hwang, T., Liu, T.-C., Sze, D. Y., Kim, J.-S., Kwon, H.-C., Oh, S. Y., Han, S.-Y., Yoon, J.-H., Hong, S.-H., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70107-4 · Cited by 521
Current Advances in Chitosan Nanoparticles Based Drug Delivery and Targeting
Garg, U., Chauhan, S., Nagaich, U., & Jain, N. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.023 · Cited by 505
Nonviral gene delivery: What we know and what is next
Gao, X., Kim, K.-S., & Liu, D. (2007) · The AAPS Journal · doi:10.1208/aapsj0901009 · Cited by 431
Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential
Escors, D., & Breckpot, K. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0063-4 · Cited by 344
Maker, A. V., Attia, P., & Rosenberg, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7746 · Cited by 343
Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice
Nakai, H., Fuess, S., Storm, T. A., Muramatsu, S.-I., Nara, Y., & Kay, M. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.214-224.2005 · Cited by 327
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321 · cited 1×
“This LDLR-mediated delivery mechanism has led to FDA approval of hepatocytetargeted delivery of siRNA for an inherited disease [37].”
BackgroundImmunity, tolerance and autoimmunity in the liver: A comprehensive review
Doherty, D. G. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.08.020 · Cited by 314
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer
Marelli, G., Howells, A., Lemoine, N. R., & Wang, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00866 · Cited by 279
Kalathil, S., Lugade, A. A., Miller, A., Iyer, R., & Thanavala, Y. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3381 · Cited by 271
YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression
Fitamant, J., Kottakis, F., Benhamouche, S., Tian, H. S., Chuvin, N., Parachoniak, C. A., Nagle, J. M., Perera, R. M., Lapouge, M., Deshpande, V., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.027 · Cited by 248
The promise of sonodynamic therapy
Trendowski, M. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9461-5 · Cited by 228
Whilding, L., Halim, L., Draper, B., Parente-Pereira, A., Zabinski, T., Davies, D., & Maher, J. (2019) · Cancers · doi:10.3390/cancers11050674 · Cited by 209
Jiang, Z., Jiang, X., Chen, S., Lai, Y., Wei, X., Li, B., Lin, S., Wang, S., Wu, Q., Liang, Q., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00690 · Cited by 207
Luo, X.-Y., Wu, K.-M., & He, X.-X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01968-w · Cited by 202
Improving the safety of cell therapy products by suicide gene transfer
Jones, B. S., Lamb, L. S., Goldman, F., & Di Stasi, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00254 · Cited by 201
Casak, S. J., Donoghue, M., Fashoyin-Aje, L., Jiang, X., Rodriguez, L., Shen, Y.-L., Xu, Y., Jiang, X., Liu, J., Zhao, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3407 · Cited by 181
Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor
Hsu, S.-H., Yu, B., Wang, X., Lu, Y., Schmidt, C. R., Lee, R. J., Lee, L. J., Jacob, S. T., & Ghoshal, K. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2013.05.007 · Cited by 173
Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
Sun, S., He, H., Yang, G., Zhang, Y., & Fu, Y. (2018) · Journal of Immunology Research · doi:10.1155/2018/2386187 · Cited by 166
Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma
Yarchoan, M. M., Agarwal, P., Villanueva, A., Rao, S., Dawson, L. A., Karasic, T. B., Llovet, J. M., Finn, R. S., Groopman, J. D., El‐Serag, H. B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0803 · Cited by 161
Lai, I. K., Swaminathan, S., Baylot, V., Mosley, A. R., Dhanasekaran, R., Gabay, M., & Felsher, D. W. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0431-x · Cited by 156
Talimogene Laherparepvec: First Global Approval
Greig, S. L. (2015) · Drugs · doi:10.1007/s40265-015-0522-7 · Cited by 150
Zhang, B.-C., Luo, B.-Y., Zou, J., Wu, P., Jiang, J., Le, J., Zhao, R., Chen, L., & Shao, J. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c17660 · Cited by 141
Moehler, M. H., Heo, J., Lee, H. C., Tak, W. Y., Chao, Y., Paik, S. W., Yim, H. J., Byun, K. S., Baron, A. D., Ungerechts, G., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1615817 · Cited by 139
Emerging therapies in advanced hepatocellular carcinoma
Medavaram, S., & Zhang, Y. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0109-6 · Cited by 127
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani, N., Derakhshani, A., Kooshkaki, O., Shadbad, M. A., Hajiasgharzadeh, K., Baghbanzadeh, A., Safarpour, H., Mokhtarzadeh, A., Brunetti, O., Yue, S. C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218305 · Cited by 120
Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States
Rich, N. E., Yopp, A. C., Singal, A. G., & Murphy, C. C. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.043 · Cited by 113
Ultrasound-Controlled CRISPR/Cas9 System Augments Sonodynamic Therapy of Hepatocellular Carcinoma
Yin, H., Sun, L., Pu, Y., Yu, J., Feng, W., Dong, C., Zhou, B., Du, D., Zhang, Y., Chen, Y., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c01143 · Cited by 108
Concepts in Oncolytic Adenovirus Therapy
Mantwill, K., Klein, F. G., Wang, D., Hindupur, S. V., Ehrenfeld, M., Holm, P. S., & Nawroth, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910522 · Cited by 107
Zhang, Y., Shen, Y., Liao, M., Mao, X., Mi, G., Chen, Y., Guo, Q., Li, W., Wang, X., Lin, N., et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.09.002 · Cited by 101
Systemic therapy of liver cancer
Demir, T., Lee, S. S., & Kaseb, A. O. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2020.12.001 · Cited by 96
Lipid-Based Drug Delivery Systems for Cancer Treatment
Arias, J. L., Clares, B., Morales, M. E., Gallardo, V., & Ruíz, M. A. (2011) · Current Drug Targets · doi:10.2174/138945011795906570 · Cited by 94
Gene Delivery Using Herpes Simplex Virus Vectors
Burton, E. A., Fink, D. J., & Glorioso, J. C. (2002) · DNA and Cell Biology · doi:10.1089/104454902762053864 · Cited by 92
Bogorad, R. L., Yin, H., Zeigerer, A., Nonaka, H., Ruda, V. M., Zerial, M., Anderson, D. G., & Koteliansky, V. (2014) · Nature Communications · doi:10.1038/ncomms4869 · Cited by 86
Yu, Q., Liu, Y., Yu, B., Hu, Y., Zhang, N., Zheng, Y., Yang, M., & Xu, F. (2020) · Advanced Science · doi:10.1002/advs.202001424 · Cited by 81
Nasr, M., Nafee, N. A., Saad, H., & Kazem, A. H. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.04.016 · Cited by 77
Wang, J., Lu, X.-X., Chen, D., Li, S., & Zhang, L. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i3.400 · Cited by 75
Wang, K., Kievit, F. M., Sham, J. G., Jeon, M., Stephen, Z. R., Bakthavatsalam, A., Park, J. O., & Zhang, M. (2015) · Small · doi:10.1002/smll.201501985 · Cited by 75
Evolving AAV-delivered therapeutics towards ultimate cures
He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 71
Zheng, A., Chevalier, N., Calderoni, M., Dubuis, G., Dormond, O., Ziros, P. G., Sykiotis, G. P., & Widmann, C. (2019) · Oncotarget · doi:10.18632/oncotarget.27361 · Cited by 70
Rochigneux, P., Chanez, B., de Rauglaudre, B., Mitry, E., Chabannon, C., & Gilabert, M. (2021) · Cancers · doi:10.3390/cancers13020271 · Cited by 70
FDA approves second BCMA-targeted CAR-T cell therapy
Mullard, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00048-8 · Cited by 68
Chouljenko, D. V., Ding, J., Lee, I., Murad, Y. M., Bu, X., Liu, G., Delwar, Z. M., Sun, Y., Yu, S., Samudio, I. J., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8110484 · Cited by 64
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)
Breitbach, C. J., Bell, J. C., Hwang, T.-H., Kirn, D. H., & Burke, J. (2015) · Oncolytic Virotherapy · doi:10.2147/ov.s59640 · Cited by 60
Rajasekaran, D., Srivastava, J., Ebeid, K., Gredler, R., Akiel, M., Jariwala, N. H., Robertson, C. L., Shen, X., Siddiq, A., Fisher, P. B., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00254 · Cited by 56
Self-citationChen, J., Shu, Z., Tong, L., Li, J., Chen, F., Han, Y., Zhao, M., & Xiong, W. H. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-114 · Cited by 54
Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease
Woitok, M. M., Zoubek, M. E., Doleschel, D., Bartneck, M., Mohamed, M. R., Kießling, F., Lederle, W., Trautwein, C., & Cubero, F. J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2571-4 · Cited by 53 · cited 1×
“Using a similar principle, LNP was generated to deliver siRNA for Jun N-terminal kinase-2 (Jnk2), which ameliorated hepatitis, fibrosis and the initiation of HCC in a spontaneous mouse model [38].”
MethodLai, C., Yu, X., Zhuo, H., Zhou, N., Xie, Y., He, J. B., Peng, Y., Xie, X.-X., Luo, G., Zhou, S., et al. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.2051 · Cited by 53
Liu, C., Chern, G., Hsu, F., Huang, K., Sung, Y., Huang, H., Qiu, J.-T. T., Wang, S., Lin, C., Wu, C., et al. (2017) · Hepatology · doi:10.1002/hep.29513 · Cited by 51
Pegylated immuno-lipopolyplexes: A novel non-viral gene delivery system for liver cancer therapy
Hu, Y., Li, K., Wang, L., Yin, S., Zhang, Z., & Zhang, Y. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.02.005 · Cited by 49
Xue, W., Feng, Y., Wang, F., Guo, Y., Li, P., Wang, L., Liu, Y.-F., Wang, Z.-W., Yang, Y., & Mao, Q.-S. (2016) · Scientific Reports · doi:10.1038/srep22149 · Cited by 49
Rinaldi, L., Guarino, M., Perrella, A., Pafundi, P. C., Valente, G., Fontanella, L., Nevola, R., Guerrera, B., Iuliano, N., Imparato, M., et al. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05604-8 · Cited by 49
Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma
Wang, Y., Huang, P.-P., Zhang, R., Ma, B.-Y., Zhou, X.-M., & Sun, Y.-F. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.326 · Cited by 44
Kuruvilla, S. P., Tiruchinapally, G., Crouch, A. C., ElSayed, M. E. H., & Greve, J. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181944 · Cited by 44
A novel role of astrocyte elevated gene‐1 (AEG‐1) in regulating nonalcoholic steatohepatitis (NASH)
Srivastava, J., Robertson, C. L., Ebeid, K., Dozmorov, M. G., Rajasekaran, D., Mendoza, R. G., Siddiq, A., Akiel, M., Jariwala, N. H., Shen, X., et al. (2017) · Hepatology · doi:10.1002/hep.29230 · Cited by 40
Self-citationKim, Y., Kim, K. T., Lee, S.-J., Hong, S., Moon, J.-Y., Yoon, E. K., Kim, S., Kim, E. O., Kang, S. H., Kim, S. K., et al. (2016) · Theranostics · doi:10.7150/thno.13621 · Cited by 37
Nie, J., Liu, Y., Yu, Q., Zhang, N., Yu, B., Chen, D., Yang, M., & Xu, F. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.030 · Cited by 35
Husseini, F., Delord, J., Fournel-Federico, C., Guitton, J., Erbs, P., Homerin, M., Halluard, C., Jemming, C., Orange, C., Limacher, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw440 · Cited by 33
Vaughan, H. J., Zamboni, C. G., Radant, N. P., Bhardwaj, P., Lechtich, E. R., Hassan, L. F., Shah, K., & Green, J. J. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.04.004 · Cited by 33
Wu, Z., Xu, X., Zhang, J.-Z., Mao, X., Xie, M., Cheng, Z., Lu, L., Duan, X., Zhang, L., & Shen, J. (2017) · Nanomaterials · doi:10.3390/nano7050110 · Cited by 30
Fang, C.-C., Wu, C.-F., Liao, Y., Huang, S.-F. K., Chen, M., & Chen, Y. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-30800-3 · Cited by 30
Surface tailored zein as a novel delivery system for hypericin: Application in photodynamic therapy
Abdelsalam, A. M., Somaida, A., Ambreen, G., Ayoub, A. M., Tariq, I., Engelhardt, K. H., Garidel, P., Fawaz, I., Amin, M. U., Wojcik, M., et al. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112420 · Cited by 30
Live and Let Die: A New Suicide Gene Therapy Moves to the Clinic
Morgan, R. A. (2012) · Molecular Therapy · doi:10.1038/mt.2011.273 · Cited by 29
Mansour, H. E. A., ElBatsh, M. M., Badawy, N., Mehanna, E. T., Mesbah, N. M., & Abo–Elmatty, D. M. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1823436 · Cited by 29
Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo
Sun, X., Xing, L., Deng, X., Hsiao, H. T., Manami, A., Koutcher, J. A., Ling, C., & Li, G. C. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.07.011 · Cited by 28
Wang, D., Chang, R., Wang, G., Hu, B., Qiang, Y., & Chen, Z. (2016) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520616666160926111911 · Cited by 26
Sharma, S., Mehak, M., Chhimwal, J., Patial, V., & Sk, U. H. (2019) · Toxicology Research · doi:10.1039/c9tx00103d · Cited by 24
Bae, Y., Song, S. J., Mun, J. Y., Ko, K. S., Han, J., & Choi, J. S. (2017) · Polymers · doi:10.3390/polym9060197 · Cited by 21
Discovery of Bacterial Deaminases That Convert 5-Fluoroisocytosine Into 5-Fluorouracil
Aučynaitė, A., Rutkienė, R., Tauraitė, D., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02375 · Cited by 21
Sia, K. C., Huynh, H. T., Chinnasamy, N., Hui, K. M., & Lam, P. Y. P. (2011) · Gene Therapy · doi:10.1038/gt.2011.131 · Cited by 18
The First Journal on Human Gene Therapy Celebrates its 25th Anniversary
Wilson, J. M. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.2528 · Cited by 4
Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma
Witzigmann, D., Grossen, P., Quintavalle, C., Lanzafame, M., Schenk, S., Tran, X.-T., Englinger, B., Hauswirth, P., Grünig, D., van Schoonhoven, S., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.023 · Cited by 4
Cited by
Liu, F., Peng, Y., Qian, H., Xiao, M. C., Ding, C. H., Zhang, X., & Xie, W. F. (2024) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13272 · Cited by 5
Metadata
- Authors
- Chakraborty, E., & Sarkar, D.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-06-04
- Volume
- 14
- Issue
- 11
- Pages
- 2798
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W4282041953
- Cited by
- 318
- References
- 96
- FWCI
- 34.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.